1. A renewal must be submitted by July 25, 2014 , containing the following information:
i. The number of subjects recruited; ii. A description of any protocol modification; iii. Any unusual and/or severe complications, adverse events or unanticipated problems involving risks to subjects or others, withdrawal of subjects from the research, or complaints about the research; iv. A summary of any recent literature, finding, or other relevant information, especially information about risks associated with the research; v. A copy of the current informed consent form; vi. The expected date of termination of this project. 2. A Final Report must be submitted at the termination of the project.
Please accept the Board's best wishes for success in your research. 
Impact and Operational Approvals
Some research may require operational approval and/or approval by another REB depending on the nature and location of the research.
Research impacting AHS (i.e., use of facilities, staff, patients)
For research undertaken by AHS staff or using AHS resources, appropriate authorizations (i.e., signatures) must be obtained from those areas where operations will be impacted by the protocol. This is to ensure that the individual responsible for the area is aware of, and able to, support your study. Complete and upload the Operational/Department Approval Form in the Document section 'Other Documents' at the end of the application.
Research impacting the University of Calgary (i.e., use of facilities, staff, students) For research undertaken by University of Calgary faculty, staff or students, or using University of Calgary resources, approval must be obtained from the PI's Department Head. Complete and upload the Operational/Department Approval Form in the Document section 'Other Documents' at the end of the application.
Research impacting the community (i.e., use of staff, facilities or members of public agencies, private organizations)
For research undertaken in the community, submit confirmation of the agency's support of the research undertaking (e.g., email, letter of support -Document section 'Other Documents').
PI attestation:
As the PI, you are assuming responsibility for the ethical conduct of the study. This includes ensuring respect for human research participants through adherence to local, provincial and national research standards (e.g., TCPS 2) and relevant legislation (e.g., Health Information Act, Hospitals Act). You are required to provide your signature on the Operational/Departmental Approval form, as an indication that you have accepted these responsibilities.
All questions preceded by a red asterisk (*) are required responses that map you to the application sections that are relevant to your study. All questions within the section to which you are mapped must be addressed.
* List the locations where the research will be undertaken:
Research will be computer based, and will be done within the city of Calgary. 
Yes No
Note: If Yes, upload the review, certificate or notice of award in the Documentation section 'Other Documents' at the end of this application.
Archived Question:
If the proposed research is above minimal risk and is not funded via a competitive peer review grant or industry-sponsored clinical trial, the REB will require evidence of scientific review. Provide information about the review process and its results if appropriate:
Archived Response:
Minimal risk survey based study.
Study Objectives and Design
The REB's main interest here is what the research will be doing with participants and he/she undertakes the study so that they can assess potential risks to the participants and how the researcher is handling them.
All acronyms must be written out in full the first time that they appear in the application form, recruiting materials and consent materials. 2) Do organizations that produce CPGs have operating procedures to manage potential COI during clinical guideline development?
3)Do organizations that produce CPGs disclose within the guideline their funding sources and the procedures for managing potential COI? 4) Is there an association between the strength of recommendations for a pharmaceutical product and the rigor of the procedures to manage/prevent potential COI? 5)Is there an association between the rigor of the guidelines producer's procedures to manage/prevent potential COI and the quality of the guidelines as defined by the AGREE guidelines assessment tool.
6)Is there an association between the financial COI of individual authors and the funding sources of CPG producers?
Methods:
Study Population: All guidelines entered in the National Guidelines Clearinghouse from Jan. 1st, 2012 to Dec. 31st, 2012.
Study Measures: https://iriss.ucalgary.ca/IRISSPROD/ResourceAdministration/Project/…Info=False&PrintPageBreak=False&PrintLogo=True&showHiddenData=False Each guideline will be analyzed for four items:
The sources of funding for the guideline producer.
The existence and basic elements of a procedure to minimize potential COI for the production of CPGs.
Presence of a disclosure statement within the guideline of funding sources and the procedures for managing potential COI.
The financial COI of the individual guideline authors.
Wherever this information is not available within the guideline text or guideline producer's website, an email survey will be sent to the guideline producer requesting the information.
Conclusion:
Given the potential for far-reaching impact of guidelines on clinical practice, it is essential that these publications are free of significant COI. Above the level of individual authors, financial COI in the form of funding for CPG producers may introduce significant bias; however, this issue is poorly established. A systematic analysis of potential COI related to funding at the guideline producer level is a key first step in defining the issue. Depending on the results of the analysis, there may be justification for an organized and uniform approach to minimizing and disclosing COI of this kind to allow end-users to reliably appraise clinical practice guidelines. The risks/discomforts of the study are minimal. The survey respondents will be asked to provide anonymous details regarding funding of clinical practice guidelines and organizational procedures relating to management of potential financial conflicts of interest.
4.0
Describe how you will manage and minimize risks and discomforts, as well as mitigate harm:
All respondents will be anonymous, and we will attempt to obtain the same information from all producers of the 2012 guidelines within the National Guidelines Clearinghouse. https://iriss.ucalgary.ca/IRISSPROD/ResourceAdministration/Project/…nfo=False&PrintPageBreak=False&PrintLogo=True&showHiddenData=False 5.0 * If your study has the potential to identify individuals who are upset, distressed, or disturbed, or warranting medical attention, describe the arrangements made to try to assist these individuals. If no arrangements have been made, please explain why:
We do not foresee any participant becoming upset, distressed, or disturbed as a result of our survey.
Reproductive Risk
1.0
Are there risks to any third parties associated with this study? There are no specific benefits to participants of the survey.
* Describe the scientific, scholarly or societal benefits of the proposed research:
Given the potential for far-reaching impact of guidelines on clinical practice, it is essential that these publications are free of significant COI. Above the level of individual authors, financial COI in the form of https://iriss.ucalgary.ca/IRISSPROD/ResourceAdministration/Project…nfo=False&PrintPageBreak=False&PrintLogo=True&showHiddenData=False funding for CPG producers may introduce significant bias; however, this issue is poorly established. A systematic analysis of potential COI related to funding at the guideline producer level is a key first step in defining the issue. Depending on the results of the analysis, there may be justification for an organized and uniform approach to minimizing and disclosing COI of this kind to allow end-users to reliably appraise clinical practice guidelines.
Benefits/Risks Analysis: Describe the relationship of benefits to risk of participation in the research:
There is no significant benefit or risk to survey respondents.
Participant Information
* Describe the population that will be included in this study:
The population is all clinical guidelines published in the National Guidelines Clearinghouse repository from Jan 1st, 2012-Dec. 31st, 2012. The population that will receive a survey are representatives for the organizations that publish the above guidelines.
* Describe and justify the inclusion criteria for participants:
All clinical guidelines published in the National Guidelines Clearinghouse repository from Jan 1st, 2012-Dec. 31st, 2012. The inclusion criteria by date is a sample of convenience.
Describe and justify the exclusion criteria for participants, if applicable:
Documents published as guidelines that do not contain any recommendations will be excluded. We are using a sample of convenience. There are 374 guidelines published in 2012 in the National Guidelines Clearinghouse. There are multiple guidelines from a single producer, which may decrease the number of organizations surveyed to approximately 300.
* Does the research specifically target aboriginal groups or communities?
Yes No Recruit Potential Participants 1.0 Recruitment 1.1 How will potential participants be identified? Describe how you will identify the people who will be approached for participation or screened for eligibility:
How will people obtain details about the research in order to make a decision about participating? (select all that apply)
Researchers will contact potential participants
Provide the locations where the participants will be recruited (e.g. educational institutions, facilities in Alberta Health Services, etc.):
By email survey. 
Informed Consent Determination
* What type of consent will you be seeking? (select all that apply)
Consent from a competent adult https://iriss.ucalgary.ca/IRISSPROD/ResourceAdministration/Project…nfo=False&PrintPageBreak=False&PrintLogo=True&showHiddenData=False
Provide justification for requesting a Waiver of Consent (minimal risk only):

How is consent to be indicated and documented? Select all that apply:
Consent implied by specific action 2.1 Except for "Signed consent form" use only, explain how the study information will be communicated and participant consent will be documented. Provide details for EACH of the option selected above:
A consent statement will be included on the survey explicitly stating that by completing the survey the respondent is giving consent for the study. An email address will be provided with the survey to which they can write to request to withdraw from the study.
3.0
6.0
Describe the circumstances and limitations of data withdrawal from the study, including the last point at which it can be done:
The only limitation will be requests after proposed completion of data analysis in Oct. 2013.
Will this study involve any group(s) where non-participants are present?
Yes No https://iriss.ucalgary.ca/IRISSPROD/ResourceAdministration/Project…nfo=False&PrintPageBreak=False&PrintLogo=True&showHiddenData=False
Research Methods and Procedures
* This study will involve the following: (select all that apply)
Use of deception or partial disclosure (not including double-blind procedures)
Interviews (in-person, telephone, email, videoconferencing, chat rooms, etc.)
Focus groups (including electronic/online focus groups)
Surveys and questionnaires (including internet surveys and questionnaires)
Behavioral tasks Test Name Test Administrator Organization Administrator's Qualifications There are no items to display
3.0
If any test results could be interpreted diagnostically, how will these be reported back to the participants?
If this study involves secondary use of data, list all original sources:
Data on potential conflicts of interest and organizational procedures for management of potential conflict of interest will be obtained, where possible, from the published guideline or from the producer's website. Wherever this information is not available, a survey will be sent by email to the guideline producer.
5.0
In research where total anonymity and confidentiality cannot be guaranteed (e.g. where participants talk in a group) what measures will be taken to protect confidentiality to the degree possible, and what information will participants be given about limits to confidentiality? All email surveys will be anonymized and data will be stored on a single password-protected personal computer and all research data files will be encrypted and password-protected.
Data Identifiers
All questions preceded by a red asterisk (*) are required responses that map you to the application sections that are relevant to your study. All questions within the section to which you are mapped must be addressed. The survey recipients' names will be collected in order to determine which recipients have responded and which will receive a reminder. Once the survey data is collected it will be anonymized. A list of the participants' affiliated organizations with corresponding codes will be maintained to ensure that there is no duplication of data. Respondents' names or other personal information will not be retained.
5.0
If applicable, describe your plans to link the data in this study with data associated with other studies (e.g. within a data repository) or with data belonging to another organization: https://iriss.ucalgary.ca/IRISSPROD/ResourceAdministration/Project…nfo=False&PrintPageBreak=False&PrintLogo=True&showHiddenData=False
Data Confidentiality and Privacy
1.0 * How will confidentiality of the data be maintained? Describe how the identity of participants will be protected both during and after the research: A list of survey recipients names and affiliated organizations will be maintained until the data collection phase is complete. From this point on a list of only the organizations will be maintained. Data will be stored on a single password-protected personal computer and all research data files will be encrypted and password-protected.
2.0
How will the Principal Investigator ensure that all study personnel are aware of their responsibilities concerning participants' privacy and the confidentiality of their information?
The principal investigator will have a meeting will all investigators to outline the responsibilities and measures to protect privacy and confidentiality of participants as outlined in this application. 1.0 * Describe the electronic security provisions and the physical security provisions: Data will be stored on a single password-protected personal computer and all research data files will be encrypted and password-protected. No hardcopies of research materials with participant identifiers will be made. The data produced in this study will not be used for future research.
External Data Access
3.0
If you plan to destroy your data, describe when and how that will be done and who will have
access. Indicate your plans for the destruction of the identifiers at the earliest opportunity https://iriss.ucalgary.ca/IRISSPROD/ResourceAdministration/Project…nfo=False&PrintPageBreak=False&PrintLogo=True&showHiddenData=False consistent with the conduct of the research and/or clinical needs: Participant names will be deleted from the master list once the data collection period has completed.
Documentation
Add documents in this section according to the headers, if applicable. Use "Other Documents" for any documents not specifically mentioned in the sections below. 
